In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic CEO takes the helm amid investor speculation:

This article was originally published in Clinica

Executive Summary

Medtronic's president and COO, William Hawkins, today succeeds Arthur Collins as the company's CEO. Mr Hawkins takes the helm amid speculation over whether he can increase the company's stock price and build up investor confidence (see Clinica No 1247, p 7). Missed earnings estimates is among the problems faced by the company. On August 21, the company's shares ended down 2% in after-hours trading following the announcement of weaker than expected first quarter sales in the company's implantable heart-regulating devices. Other problems include delays in getting new products to market and the lengthy transformation of insulin pump company MiniMed into a strong performing subsidiary. If Mr Hawkins cannot address these problems, some analysts believe that Medtronic will risk becoming an acquisition target. In-depth analysis to follow.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel